Disclosed herein, inter alia, are a method, system and a kit for improving a defined condition in a subject, the method comprising selecting a set of one or more correction zones, being surface zones on the surface of the subject's skin or defined angular zones in the subject's field of view, the one or more correction zones being associated with the condition; and placing the one or more correcting elements in said one or more correction zones to thereby cause improvement in said condition. Also provided herein are methods and systems for providing such correction zones related to a defined condition in a subject or to a defined cause in a subject being associated with a defined condition.

Provided herein are needle assemblies for intravitreal injection of an implant into an eye of a patient through an unsheathed state and a sheathed state. Such needle assemblies are precise and accurate for proper treatment and prevent further damage to the eye.

Systems and methods are provided for generating and applying biomimicry tear film layers to a cornea surface. An example method includes forming a multiple layered tear film that are optically transparent, ultra-thin, and smoothly conforming to cornea surface. The multiple layered tear film can include a biomimicry adhesive layer, a biomimicry aqueous layer, and a biomimicry lipid layer. An atomizer/nebulizer/micronizer can be used to generate and applying the biomimicry tear film layers.

The present disclosure relates to relates to systems and methods for on-demand delivery of a therapeutic agent from an eye mounted device. Particularly, aspects of the present invention are directed to a method of delivering a therapeutic agent, the method including receiving, at a controller of a therapeutic agent release and delivery device, a first command signal for delivery of a therapeutic agent based on a dosing time window. Upon receipt of the first command signal, the controller determines whether one or more compliance conditions are satisfied. When the one or more conditions are satisfied, the controller initiate a release and delivery protocol that commands a signal generator to generate and send a second command signal causing a capacitor or one or more circuits to deliver an actuation signal causing one or more therapeutic agent delivery mechanisms to open and release the therapeutic agent from one or more reservoirs.

The present invention provides a cannulation device for administering an active agent containing composition to the suprachoroidal space or supraciliary space. The invention provides methods of treatment of an ocular disease or condition accordingly. The invention also provides compositions for use in a method of treatment of an ocular disease or condition for delivery into the suprachoroidal space or supraciliary space.

The present invention relates to an ultrasound contrast agent for use in treating a retina disorder by transiently disrupting the blood-retinal barrier (BRB) of a human, wherein the ultrasound contrast agent is administered just before and/or during the application, to the retina of the human, of an unfocused ultrasound (US) beam. The present invention further relates to a therapeutically active agent for use in treating a retina disorder in a human, wherein the therapeutically active agent is to be delivered in combination with an ultrasound contrast agent, which is administered before and/or during the application, to the retina of the human, of an unfocused ultrasound (US) beam in order to transiently disrupting the blood-retinal barrier (BRB) of the human, to allow the therapeutically active agent to cross the BRB and to target the retina. The present invention also relates to an eye ultrasound delivery device that may be used to treat a retina disorder.

A therapeutic device for extended release drug delivery including a refillable reservoir configured to receive a therapeutic agent and having an outlet for delivery of the therapeutic agent to a patient from the reservoir over an extended period. A porous structure is coupled near the outlet of the reservoir, the porous structure formed of sintered material. A barrier layer is coupled to the reservoir on or adjacent a surface of the porous structure such that the therapeutic agent passes through both the porous structure and the barrier layer upon delivery from the reservoir through the outlet. The porous structure is tuned to deliver the therapeutic agent at a diffusion rate and the barrier layer is adapted to block passage of particles having an average particle size within an average particle size range that is outside an average particle size range blocked by the porous structure. Related methods and systems are provided.

Implant delivery devices, methods of device assembly and methods of using those devices are presented where the delivery device uses an automatic implant delivery mechanism that eliminates variability in pusher wire speeds by providing a needle assembly having one or more implants positioned within a proximal end of a needle cannula, a dampener assembly and a shuttle assembly located within a housing along with the activation member which holds the shuttle assembly in cocked or pre-tensioned state. A lock can be engaged with the activation member to prevent premature firing or triggering of the device.

The present embodiments relate to a method of treating dry eyes. The method includes a plurality of visits to an eye doctor with each even numbered visit focused on a first eye and each odd numbered visit focused on a second eye. The plurality of visits comprises use of intense pulsed light (“IPL”) therapy, low level light therapy, an ocular nebulizer, dehydrated amniotic membranes, biologic eye drops, advanced lubricants, eyelid debridement, meibomian gland imaging and a slit lamp.

An ocular implant for treating glaucoma is provided, which may include any number of features. More particularly, the present invention relates to implants that facilitate the transfer of fluid from within one area of the eye to another area of the eye. One feature of the implant is that it includes a proximal inlet portion and a distal inlet portion adapted to be inserted into the anterior chamber of the eye, and an intermediate portion adapted to be inserted into Schlemm's canal. Another feature of the implant is that it can be biased to assume a predetermined shape to aid in placement within the eye.